Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
REMoDL-A
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
- NCT04546620 ↗
- Active, not recruiting
- University Hospital Southampton NHS Foundation Trust
- Focused
We haven't built an HCP commentary report on REMoDL-A (acalabrutinib in previously untreated diffuse large B-cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REMoDL-A so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- R-CHOP; R-CHOP + acalabrutinib
- Arms
- Arm A Control · Active comparator
- Arm B Experimental · Experimental
- Enrollment
- 453 (estimated)
- Primary outcomes
- To establish if combining acalabrutinib with R-CHOP improves efficacy, compared to RCHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.
- Sponsor
- University Hospital Southampton NHS Foundation Trust with AstraZeneca
- Start
- Oct 19, 2021
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04546620 · updated Apr 30, 2026